Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PUMA BIOTECHNOLOGY, INC. Director's Dealing 2017

Jul 24, 2017

33488_dirs_2017-07-24_31333b27-5e97-498d-b82b-d330e9850a20.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK: 0001401667
Period of Report: 2017-07-20

Reporting Person: EYLER CHARLES R (SEE REMARKS)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-07-20 COMMON STOCK S 662 $95.1527 Disposed 30018 Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in two transactions with one transaction pricing at $95.151 and the other transaction pricing at $95.701. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price set forth in this footnote.